Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + HAIC + SBRT for unresectable hepatocellular carcinoma
ChiCTR2500110280Phase 4Recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Hunan Provincial People's Hospital. Primary endpoint: Objective response rate. Started Oct 2025; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500110280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110280.